Human Antibodies & Hybridomas

31 March – 2 April 2014, Federation of Austrian Industry, Industriehaus-Verein, Schwarzenbergplatz 4, A-1030 Vienna, Austria

  • Increase font size
  • Default font size
  • Decrease font size

Day Three

Final Conference Programme | Wednesday 2nd April

SESSION 10:
BIOASSAYS/TECHNOLOGY II

Moderator: Sachdev Sidhu (University of Toronto, Toronto, Ontario, Canada)

08.30-08.50
‘Novel human antibody-like molecules as therapeutics’
Lynn Macdonald (Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA)

08.50-09.10
‘High-throughput design, production, and evaluation of multi-specific antibodies’
Maria Wendt (Genedata Biologics, Basel, Switzerland)

09.10-09.30
‘Rapid discovery and development of human and rabbit monoclonal antibodies from memory B cells using a highly efficient immortalization method’
T. Beaumont, P.M. van Helden, M.J. Kwakkenbos, I. Lodewijks, A.Q. Bakker and H. Spits (AIMM Therapeutics, Amsterdam, The Netherlands)

09.30-09.50
‘An open cell free protein synthesis platform to discover novel antibodies and bispecifics’
Aaron Sato (Sutro Biopharma, South San Francisco, California, USA)

09.50-10.10
‘Innovative tools and approaches for optimizing multicolor panel design’
Line De Kimpe (BD Biosciences Europe, Le Pont-de-Claix, France)

10.10-10.30
‘Bacterial artificial chromosomes as expression vehicles for improved protein expression’
W. Sommeregger, A. Gili, K. Zboray, T. Sterovsky, E. Casanova and R. Kunert (University of Natural Resources and Life Sciences BOKU, Vienna, Austria)

10.30-11.00
Coffee Break

SESSION 11:
INFECTIOUS DISEASE

Moderator: Yan Wu (Kadmon Pharmaceuticals LLC, New York, USA)

11.00-11.25
‘Functions of V2 antibodies which may protect against HIV-1 infection’
Miroslaw K. Gorny (New York University, New York, USA)

11.25-11.50
‘Safety and pharmacokinetics of GNbAC1, a humanized IgG4, in patients with multiple sclerosis’
Alois Lang (Geneuro SA, Geneva, Switzerland)

11.50-12.15
‘Discovery of unique human monoclonal antibodies that counteract staphylococcal virulence factors’
Eszter Nagy (Arsanis Biosciences GmbH, Vienna, Austria)

12.15-12.40
‘ALX-0171: An inhaled Nanobody for the treatment of RSV infection’
Erik Depla (Ablynx BV, Zwijnaarde, Belgium)

12.40-13.00
‘Human monoclonal antibodies for making human monoclonal antibodies safer: A possible combined use of an anti-JCV human Mab and Natalizumab’
Roberto Burioni (Universita Vita-Salute San Raffaele, Milan, Italy)

13.00-14.00
Lunch Break & Posters Breakdown

SESSION 12:
DRUG CONJUGATES

Moderator: Alois Lang (Geneuro SA, Geneva, Switzerland)

14.00-14.30
‘Optimized antibody drug conjugate design using SMARTag™ technology’
Gregory T. Bleck (Catalent Pharma Solutions, Madison, Wisconsin, USA)

14.30-15.00
‘Antibody-drug conjugates (ADCs): After Kadcyla, what’s next?’
Victor S. Goldmacher and John Lambert (ImmunoGen Inc., Waltham, Massachusetts, USA)

15.00-15.30
‘Novel approached to the development of antibody drug conjugates’
Roger R. Beerli (NBE-Therapeutics LLC, Basel, Switzerland)

15.30-15.50
Tea Break

SESSION 13:
INFECTIOUS DISEASE

Moderator: Mark C. Glassy (IMSA Foundation/Nascent Biologics Inc., San Diego, California, USA)

15.35-16.15
‘A functionally oligoclonal Mab mixture to treat Clostridium difficile infections’
David P. Humphreys (UCB-New Medicines, Slough, Berkshire, UK)

16.15-16.35
‘Glycoengineered anti viral monoclonal IgG antibodies produced in plants exhibit enhanced in vitro and in vivo activities’
Herta Steinkellner, Friedrich Altmann and Alexandra Castilho (University of Natural Resources and Life Sciences BOKU, Vienna, Austria)

16.35
Closing Remarks
Mark C. Glassy (IMSA Foundation/Nascent Biologics Inc., San Diego, California, USA)

* This final programme is correct at the time of printing. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the final conference programme.

 

HAH 2014 Sponsors

  • MedImmune
  • InCellart
  • Kadmon
  • Fenwick & West
  • ImmunoGen
  • Geneuro
  • Symphogen
  • Arsanis Biosciences
  • Retroscreen Virology
  • ModiQuest Research
  • MacroGenics
  • Morphosys
  • MAB Discovery
  • Aldevron
  • Nascent Biologics
  • CytomX Therapeutics
  • FWF
  • BioToP
  • UCB
  • Regeneron
  • Mapp Biopharmaceutical
  • Catalent
  • Boehringer Ingelheim
  • Adimab
  • Merck Serono
  • Fusion Antibodies
  • VIBT-BOKU
  • ImClone Systems
  • F-star
  • Polymun Scientific
  • OMT

HAH 2014 Downloads

HAH 2014 Leaflet

HAH 2014 Mailing List

Name
E-mail Address
What is 1+4-2?